Mario Schlosser Sells 31,422 Shares of Oscar Health (NYSE:OSCR) Stock

Oscar Health, Inc. (NYSE:OSCR) Director Mario Schlosser sold 31,422 shares of the company’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $31.45, for a total value of $988,221.90. Following the transaction, the director directly owned 449,444 shares of the company’s stock, valued at $14,135,013.80. This represents a 6.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Mario Schlosser also recently made the following trade(s):

• On Friday, August 28th, Mario Schlosser sold 150,000 shares of Oscar Health stock. The stock was sold at an average price of $30.79, for a total value of $4,618,500.00.
• On Thursday, August 27th, Mario Schlosser sold 600,000 shares of Oscar Health stock. The stock was sold at an average price of $30.34, for a total transaction of $18,204,000.00.
• On Tuesday, June 23rd, Mario Schlosser sold 147,500 shares of Oscar Health stock. The stock was sold at an average price of $29.38, for a total transaction of $4,333,550.00.
• On Tuesday, June 23rd, Mario Schlosser sold 880,000 shares of Oscar Health stock. The stock was sold at an average price of $29.38, for a total transaction of $25,854,400.00.

Oscar Health Stock Down 4.1%

Oscar Health stock opened at $31.64 on Thursday. The company has a market cap of $9.77 billion, a P/E ratio of 22.60, a price-to-earnings-growth ratio of 0.68 and a beta of 2.37. Oscar Health, Inc. has a 1-year low of $10.69 and a 1-year high of $33.55. The company has a fifty day simple moving average of $30.58 and a 200 day simple moving average of $23.14. The company has a current ratio of 1.09, a quick ratio of 1.09 and a debt-to-equity ratio of 0.21.

Oscar Health (NYSE:OSCR) last issued its quarterly earnings results on Thursday, August 6th. The company reported $1.10 EPS for the quarter, topping the consensus estimate of $0.40 by $0.70. Oscar Health had a net margin of 3.60% and a return on equity of 38.45%. The firm had revenue of $4.88 billion for the quarter, compared to analysts’ expectations of $4.73 billion. During the same period in the previous year, the firm posted ($0.89) EPS. The company’s revenue for the quarter was up 70.4% on a year-over-year basis. Research analysts anticipate that Oscar Health, Inc. will post 1.54 earnings per share for the current fiscal year.

Key Oscar Health News

Here are the key news stories impacting Oscar Health this week:

• Positive Sentiment: A recent outlook article argues that Oscar Health’s future remains bright, supported by its technology-driven insurance platform, expanding membership opportunities and potential for continued earnings growth. The future looks bright for Oscar Health stock
• Positive Sentiment: The company’s latest quarterly results were substantially better than expected: earnings per share came in at $1.10 versus the $0.40 consensus estimate, while revenue rose 70.4% year over year to $4.88 billion. Analysts expect full-year EPS of approximately $1.54.
• Positive Sentiment: Institutional ownership remains high at approximately 75.7%, and several funds increased their Oscar Health holdings during the second quarter. Analyst sentiment has also improved in some cases, including a Zacks Research upgrade to “strong buy.”
• Neutral Sentiment: Oscar Health’s chief accounting officer Victoria Baltrus sold 958 shares for $30,129 under a pre-arranged Rule 10b5-1 plan. The filing said the sale covered tax withholding tied to vested equity awards; she retained 213,631 shares. Oscar Health CAO stock sale
• Neutral Sentiment: Director Mario Schlosser, CFO Richard Blackley, Adam Mcananey and Janet Liang also reported stock sales totaling roughly $2.5 million. Each transaction was conducted under a 10b5-1 plan and attributed to tax obligations, while all sellers retained sizable positions.
• Negative Sentiment: The cluster of insider selling may nevertheless weigh on sentiment, particularly because the transactions occurred near OSCR’s 52-week high. The stock’s average analyst rating remains “hold,” with a consensus price target of $26.22, below recent trading levels.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Tidal Investments LLC bought a new stake in shares of Oscar Health during the second quarter worth approximately $2,240,000. Integrated Wealth Concepts LLC acquired a new stake in Oscar Health during the 2nd quarter worth approximately $232,000. IFP Advisors Inc lifted its holdings in Oscar Health by 69.5% during the 2nd quarter. IFP Advisors Inc now owns 2,139 shares of the company’s stock worth $61,000 after purchasing an additional 877 shares during the last quarter. Mraz Amerine & Associates Inc. bought a new stake in Oscar Health in the 2nd quarter valued at $284,000. Finally, Allworth Financial LP grew its holdings in Oscar Health by 124.9% in the 2nd quarter. Allworth Financial LP now owns 2,031 shares of the company’s stock valued at $58,000 after buying an additional 1,128 shares in the last quarter. 75.70% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on OSCR. UBS Group raised their price target on Oscar Health from $20.00 to $26.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Barclays increased their price objective on Oscar Health from $35.00 to $39.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Piper Sandler reissued an “overweight” rating and issued a $36.00 target price on shares of Oscar Health in a research note on Tuesday, July 28th. Zacks Research upgraded shares of Oscar Health from a “hold” rating to a “strong-buy” rating in a report on Monday, July 6th. Finally, Robert W. Baird set a $27.00 price target on shares of Oscar Health in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $26.22.

About Oscar Health

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.